Acrivon Therapeutics Inc
ACRV
Company Profile
Business description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Contact
480 Arsenal Way
Suite 100
WatertownMA02472
USAT: +1 617 207-8979
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
78
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,826.40 | 15.50 | -0.18% |
CAC 40 | 7,723.47 | 27.20 | 0.35% |
DAX 40 | 24,073.67 | 286.22 | 1.20% |
Dow JONES (US) | 44,406.36 | 422.17 | -0.94% |
FTSE 100 | 8,806.53 | 16.38 | -0.19% |
HKSE | 23,887.83 | 28.23 | -0.12% |
NASDAQ | 20,412.52 | 188.59 | -0.92% |
Nikkei 225 | 39,587.68 | 223.20 | -0.56% |
NZX 50 Index | 12,755.74 | 9.21 | -0.07% |
S&P 500 | 6,229.98 | 49.37 | -0.79% |
S&P/ASX 200 | 8,589.30 | 13.70 | -0.16% |
SSE Composite Index | 3,473.13 | 0.81 | 0.02% |